Abstract |
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ( statins) are a common and effective treatment for hypercholesterolemia, with a low overall rate of side-effects. The most common complication is some degree of skeletal muscle myopathy, ranging from painless serum creatine kinase elevations to rhabdomyolysis. Unfortunately, the likelihood and/or severity of complications increases with the combination of statin treatment and physical activity. The specific pathways that mediate statin-associated myopathy are unclear, and research directly addressing the exacerbation with exercise is limited. Potential mechanisms include the induction of skeletal muscle fiber apoptosis, alterations in ubiquitin- proteasome pathway activity, mitochondrial dysfunction, and terpenoid depletion. In this review we provide an overview of research that specifically addresses the combination of statin-associated myopathy and physical activity and highlight some deficiencies in the available literature, as well as future directions for this important subset of statin-associated myopathy.
|
Authors | Benjamin M Meador, Kimberly A Huey |
Journal | Muscle & nerve
(Muscle Nerve)
Vol. 42
Issue 4
Pg. 469-79
(Oct 2010)
ISSN: 1097-4598 [Electronic] United States |
PMID | 20878737
(Publication Type: Journal Article, Review)
|
Chemical References |
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Glycogen
- Creatine Kinase
|
Topics |
- Creatine Kinase
(blood)
- Exercise
- Glycogen
(metabolism)
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(adverse effects, therapeutic use)
- Hypercholesterolemia
(drug therapy)
- Muscle, Skeletal
(metabolism)
- Muscular Diseases
(etiology, physiopathology)
- Physical Education and Training
- Risk Assessment
- Risk Factors
|